These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3420571)

  • 61. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 62. Drug-induced cancer.
    Prescrire Int; 2010 Feb; 19(105):21. PubMed ID: 20455337
    [No Abstract]   [Full Text] [Related]  

  • 63. Postmarketing management of drug use: toward rational public policy.
    Spitzer WO; Hutchinson T; Lane D
    CMAJ; 1987 May; 136(10):1022-4. PubMed ID: 3567760
    [No Abstract]   [Full Text] [Related]  

  • 64. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 65. Use of an algorithm to evaluate published reports of adverse drug reactions.
    Case B; Oszko MA
    Am J Hosp Pharm; 1991 Jan; 48(1):121-2. PubMed ID: 2000870
    [No Abstract]   [Full Text] [Related]  

  • 66. Overview of different logistical approaches to postmarketing surveillance.
    Strom BL
    J Rheumatol Suppl; 1988 Oct; 17():9-13. PubMed ID: 3204621
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [When can the cases of toxic or adverse effects of drugs be rejected? 80 cases].
    Lagier G; Castot A; Sabouraud S; de Cremoux P; Efthymiou ML
    Therapie; 1990; 45(5):435-6. PubMed ID: 2260040
    [No Abstract]   [Full Text] [Related]  

  • 68. [30 years' spontaneous recording systems of German physicians--results and experiences].
    Kimbel KH
    Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503
    [No Abstract]   [Full Text] [Related]  

  • 69. [Physician and pharmaceutical industry. II. Postmarketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):36-41. PubMed ID: 1728761
    [No Abstract]   [Full Text] [Related]  

  • 70. Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
    Marley JE
    Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Postmarketing surveillance of adverse drug reactions: problems and solutions.
    Lortie FM
    CMAJ; 1986 Jul; 135(1):27-32. PubMed ID: 3719483
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Drug-induced memory disorders.
    Prescrire Int; 2010 Feb; 19(105):29. PubMed ID: 20455342
    [No Abstract]   [Full Text] [Related]  

  • 73. [4-year experience in drug surveillance].
    Capellà D; Avila P; Cabeza L; Moreno V; Vidal X; Laporte JR
    Med Clin (Barc); 1988 Jun; 91(3):93-6. PubMed ID: 3172912
    [No Abstract]   [Full Text] [Related]  

  • 74. [Adverse effects of drugs and computerized registries--a threat or a possibility?].
    Bergman U; Linnarsson R; Boethius G; Matell G; Keisu M; Peterson H; Kalles I; Wiholm BE; Krakau I; Westerholm B
    Lakartidningen; 1989 Apr; 86(16):1506-8. PubMed ID: 2725139
    [No Abstract]   [Full Text] [Related]  

  • 75. Assessing risk in postmarketing surveillance.
    Cerrito PB; Cerrito JC
    J Biopharm Stat; 1991; 1(2):221-35. PubMed ID: 1844698
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nonlinear neural mapping analysis of the adverse effects of drugs.
    Domine D; Guillon C; Devillers J; Lacroix R; Lacroix J; Doré JC
    SAR QSAR Environ Res; 1998; 8(1-2):109-20. PubMed ID: 9517012
    [TBL] [Abstract][Full Text] [Related]  

  • 77. With more follow-up.
    Prescrire Int; 2011 Feb; 20(113):32. PubMed ID: 21488585
    [No Abstract]   [Full Text] [Related]  

  • 78. [Limitations of spontaneous reporting and ways of improving the quality of the data].
    Boschetti C; Borghi C; Canti D; Cortellaro M
    Clin Ter; 1988 Dec; 127(6):421-9. PubMed ID: 2977315
    [No Abstract]   [Full Text] [Related]  

  • 79. [Evaluation of the therapeutic value of drugs--a task of clinical pharmacology].
    Herken H; Abshagen U
    Gynakologe; 1988 Mar; 21(1):14-20. PubMed ID: 3371753
    [No Abstract]   [Full Text] [Related]  

  • 80. [Goals and limits of spontaneous detection of unwanted drug side effects].
    Mathias B; Piper C; Lasek R
    Internist (Berl); 1990 Jul; 31(7):448-55. PubMed ID: 2203707
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.